{'fraction_non_alphanumeric': 0.023728813559322035, 'fraction_numerical': 0.00423728813559322, 'mean_word_length': 5.151041666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Angiotensin II Increases Cancer Stem Cell-like Phenotype in Lung Cancer Cells.

BACKGROUND
Cancer stem cells (CSCs) have been proposed as important players in cancer progression, metastasis, and chemotherapeutic resistance in many cancers, including lung cancer. However, effects of the endogenous substance angiotensin II (ANG II) on cancer stem cell-like phenotype in lung cancer are largely unknown.


MATERIALS AND METHODS
Human lung cancer cells were treated with non-cytotoxic concentrations of ANG II. The CSC phenotype was evaluated by spheroid formation, 3D culture, and anchorage-independent growth assays. The expression levels of CSC makers were determined by western blot analysis.


RESULTS
ANG II significantly increased the ability of lung cancer cells to form spheroids. ANG II also increased the growth of cancer cells in a 3D culture Matrigel-based assay and facilitated cancer cell survival in an anchorage-independent condition. Western blot analysis revealed that cell treatment with ANG II significantly up-regulated CD133 levels.


CONCLUSION
The present study revealed that the endogenous substance ANG II enhances CSC-like phenotype in lung cancer cells.